

Wright Medical Group, Inc.
Segment Profitability Information

Three Months Ended March 31, 2013

	U.S.	International	BioMimetic	Corporate	Other ⁽¹⁾	Total
Sales	\$ 42,761	\$ 13,532	\$ -	\$ -	\$ -	\$ 56,293
Gross Profit	33,865	8,987	-	(148)	(108)	42,596
Operating income (loss)	6,987	2,192	(1,311)	(12,302)	(8,792)	(13,226)
Operating income (loss) as a percent of net sales	16.3%	16.2%	N/A	N/A	N/A	-23.5%
Depreciation expense	2,145	632	39	630	-	3,446
Amortization expense	615	75	86	-	830	1,606
Non-cash stock-based compensation expense	-	-	-	1,613	-	1,613
Other	-	-	-	-	7,962	7,962
Adjusted EBITDA	9,747	2,899	(1,186)	(10,059)	-	1,401

(1) Other consists exclusively of the reconciling items from Operating Income, as reported to Operating Income, as adjusted.

Three Months Ended June 30, 2013

	U.S.	International	BioMimetic	Corporate	Other ⁽¹⁾	Total
Sales	\$ 42,640	\$ 17,932	\$ -	\$ -	\$ -	\$ 60,572
Gross Profit	35,263	11,083	-	(143)	(195)	46,008
Operating income (loss)	6,099	3,323	(3,863)	(13,425)	(5,315)	(13,181)
Operating income (loss) as a percent of net sales	14.3%	18.5%	N/A	N/A	N/A	-21.8%
Depreciation expense	2,196	533	117	657	-	3,503
Amortization expense	1,803	89	169	-	717	2,778
Non-cash stock-based compensation expense	-	-	-	2,892	-	2,892
Other	-	-	-	-	4,598	4,598
Adjusted EBITDA	10,098	3,945	(3,577)	(9,876)	-	590

(1) Other consists exclusively of the reconciling items from Operating Income, as reported to Operating Income, as adjusted.

Six Months Ended June 30, 2013

	U.S.	International	BioMimetic	Corporate	Other ⁽¹⁾	Total
Sales	\$ 85,401	\$ 31,464	\$ -	\$ -	\$ -	\$ 116,865
Gross Profit	69,128	20,070	-	(291)	(303)	88,604
Operating income (loss)	13,086	5,515	(5,174)	(25,727)	(14,107)	(26,407)
Operating income (loss) as a percent of net sales	15.3%	17.5%	N/A	N/A	N/A	-22.6%
Depreciation expense	4,341	1,165	156	1,287	-	6,949
Amortization expense	2,418	164	255	-	1,547	4,384
Non-cash stock-based compensation expense ⁽²⁾	-	-	-	4,505	-	4,505
Other	-	-	-	-	12,560	12,560
Adjusted EBITDA	19,845	6,844	(4,763)	(19,935)	-	1,991

(1) Other consists exclusively of the reconciling items from Operating Income, as reported to Operating Income, as adjusted.

(2) For the six months ended June 30, 2013, amount excludes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options, which is included in "Other".

Three Months Ended September 30, 2013

	U.S.	International	BioMimetic	Corporate	Other ⁽¹⁾	Total
Sales	\$ 42,998	\$ 14,643	\$ -	\$ -	\$ -	\$ 57,641
Gross Profit	36,599	8,281	-	(100)	(1,176)	43,604
Operating income (loss)	6,310	34	(3,494)	(14,323)	(221,086)	(232,559)
Operating income (loss) as a percent of net sales	14.7%	0.2%	N/A	N/A	N/A	-403.5%
Depreciation expense	2,030	561	119	605	-	3,315
Amortization expense	442	84	191	-	625	1,342
Non-cash stock-based compensation expense	-	-	-	2,672	-	2,672
Other	-	-	-	-	220,461	220,461
Adjusted EBITDA	8,782	679	(3,184)	(11,046)	-	(4,769)

(1) Other consists exclusively of the reconciling items from Operating Income, as reported to Operating Income, as adjusted.

Nine Months Ended September 30, 2013

	U.S.	International	BioMimetic	Corporate	Other ⁽¹⁾	Total
Sales	\$ 128,399	\$ 46,107	\$ -	\$ -	\$ -	\$ 174,506
Gross Profit	105,727	28,351	-	(391)	(1,479)	132,208
Operating income (loss)	19,396	5,549	(8,668)	(40,050)	(235,193)	(258,966)
Operating income (loss) as a percent of net sales	15.1%	12.0%	N/A	N/A	N/A	-148.4%
Depreciation expense	6,371	1,726	275	1,892	-	10,264
Amortization expense	2,860	248	446	-	2,172	5,726
Non-cash stock-based compensation expense ⁽²⁾	-	-	-	7,177	-	7,177
Other	-	-	-	-	233,021	233,021
Adjusted EBITDA	28,627	7,523	(7,947)	(30,981)	-	(2,778)

(1) Other consists exclusively of the reconciling items from Operating Income, as reported to Operating Income, as adjusted.

(2) For the nine months ended September 30, 2013, amount excludes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options, which is included in "Other".

Three Months Ended December 31, 2013

	U.S.	International	BioMimetic	Corporate	Other ⁽¹⁾	Total
Sales	\$ 49,249	\$ 18,575	\$ -	\$ -	\$ -	\$ 67,824
Gross Profit	40,815	11,278	-	(113)	(1,579)	50,401
Operating income (loss)	6,873	(788)	(4,073)	(12,899)	(12,353)	(23,240)
Operating income (loss) as a percent of net sales	14.0%	-4.2%	N/A	N/A	N/A	-34.3%
Depreciation expense	2,467	638	119	896	-	4,120
Amortization expense	647	396	77	-	630	1,750
Non-cash stock-based compensation expense	-	-	-	2,481	-	2,481
Other	-	-	-	-	11,723	11,723
Adjusted EBITDA	9,987	246	(3,877)	(9,522)	-	(3,166)

(1) Other consists exclusively of the reconciling items from Operating Income, as reported to Operating Income, as adjusted.

Twelve Months Ended December 31, 2013

	U.S.	International	BioMimetic	Corporate	Other ⁽¹⁾	Total
Sales	\$ 177,648	\$ 64,682	\$ -	\$ -	\$ -	\$ 242,330
Gross Profit	146,542	39,629	-	(504)	(3,058)	182,609
Operating income (loss)	26,269	4,761	(12,742)	(52,949)	(247,545)	(282,206)
Operating income (loss) as a percent of net sales	14.8%	7.4%	N/A	N/A	N/A	-116.5%
Depreciation expense	8,838	2,364	394	2,788	-	14,384
Amortization expense	3,507	644	523	-	2,802	7,476
Non-cash stock-based compensation expense ⁽²⁾	-	-	-	9,658	-	9,658
Other	-	-	-	-	244,743	244,743
Adjusted EBITDA	38,614	7,769	(11,825)	(40,503)	-	(5,945)

(1) Other consists exclusively of the reconciling items from Operating Income, as reported to Operating Income, as adjusted.

(2) For the twelve months ended December 31, 2013, amount excludes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options, which is included in "Other".

Wright Medical Group, Inc.
Segment Sales Information

	Q1 2013	Q2 2013	Q3 2013	Q4 2013	FY 2013
U.S.					
Foot and Ankle	27,763	26,957	27,727	33,197	115,644
Upper Extremity	4,114	4,473	4,317	4,519	17,423
Biologics	10,453	10,381	10,685	11,042	42,561
Other	431	829	269	491	2,020
Total U.S.	42,761	42,640	42,998	49,249	177,648
International					
Foot and Ankle	7,314	10,359	7,506	9,839	35,018
Upper Extremity	1,948	1,614	1,616	2,062	7,240
Biologics	3,204	4,710	4,499	4,818	17,231
Other	1,066	1,249	1,022	1,856	5,193
Total International	13,532	17,932	14,643	18,575	64,682
Global					
Foot and Ankle	35,077	37,316	35,233	43,036	150,662
Upper Extremity	6,062	6,087	5,933	6,581	24,663
Biologics	13,657	15,091	15,184	15,860	59,792
Other	1,497	2,078	1,291	2,347	7,213
Total Extremities	56,293	60,572	57,641	67,824	242,330